Methylated DNA Detect in Paraneoplastic Syndrome of Nervous System

Peking University

Status: Completed

Conditions: Paraneoplastic Neurological Syndrome

Treatments: Other: Positive methylated DNA; Other: Lung cancer; Other: Suspected lung cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04454853

PUTH2017351

Details and patient eligibility

About

The purpose of this study is to verify whether the cell-free DNA of lung cancer in the blood can be used as a biomarker for early diagnosis and prognosis evaluation of patient with paraneoplastic syndrome of the nervous system.

Full description

Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible in the neuropathy. The disease is a rare clinical syndrome, and lung cancer is the most common type of tumor that causes PNS.If PNS can be diagnosed when there are no tumor symptoms, not only can the cause of PNS be identified, but early tumors can be found for treatment time, and measures can be taken in the early stages of the tumor to improve survival. Tumor free DNA (cell-free DNA, cfDNA) methylation detection is to determine the cancer condition and cancer type of the subject by detecting the methylation of free DNA released by tumor cells. In normal cells, tumor suppressor genes are expressed and proto-oncogenes are silenced; in tumor cells, tumor suppressor genes are hypermethylated and silenced, and oncogenes are hypomethylated and activated. The release of free DNA into the blood will be quickly cleared in tens of minutes to several hours, which can reflect the body's cell damage in real time, and is of great significance for monitoring the early occurrence and development of the disease. At present, the sensitivity of lung cancer cf-DNA detection technology is close to 100%, and the specificity is 94%, which is an effective detection technology for early detection of lung cancer.

Enrollment: 40 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The agnogenic typical neurological syndromes (including encephalomyelitis, marginal encephalitis, subacute cerebellar degeneration, strabismus ocular clonic-myoclonus, subacute sensory neuron disease, Lambert-Eaton myasthenic syndrome, skin Myositis, etc.) patient who predisposed to a tumor.
• Pathologically confirmed as lung cancer or suggested as lung cancer patient by imaging (pulmonary CT/Positron Emission Tomography-CT), tumor biomarkers, anti-brain tissue antibodies, etc.

Exclusion criteria

• Lacunar infarction
• Aortic atherosclerotic cerebral infarction
• Clear cardiogenic cerebral infarction
• Other related system diseases (arteritis, vascular dissection, migraine and vasospasm, etc.)

Trial design

40 participants in 4 patient groups

Lung cancer with positive methylated DNA

Description:

Blood DNA methylation abnormalities are found in lung cancer.

Treatment:

Other: Positive methylated DNA

Other: Lung cancer

Lung cancer with negative methylated DNA

Description:

Blood DNA methylation abnormalities are not found in lung cancer.

Treatment:

Other: Lung cancer

Suspected lung cancer with positive methylated DNA

Description:

Blood DNA methylation abnormalities are found in suspected lung cancer.

Treatment:

Other: Suspected lung cancer

Other: Positive methylated DNA

Suspected lung cancer with negative methylated DNA

Description:

Blood DNA methylation abnormalities are not found in suspected lung cancer.

Treatment:

Other: Suspected lung cancer